Skip to main content

OncoDNA Gains UK Reimbursement for OncoStrat&Go

NEW YORK (GenomeWeb) – OncoDNA said today that a number of private health insurers, including BUPA Global Insurance, will now reimburse for its OncoStrat&Go testing in the United Kingdom.

OncoStrat&Go is a combined liquid biopsy and tissue test intended to provide a complete genetic profile of a patient's tumor to predict response to targeted, immunotherapeutic, and chemotherapy treatments.

BUPA Global has created a specific code for the reimbursement of the test, while other UK insurers will use a generic code, OncoDNA said.

OncoDNA CEO Jean-Pol Detiffe said in a statement that the agreements make it possible for many more cancer patients in the UK to access its tests.

"Oncologists in need of a solution for their patients should now have easier access to this test and hopefully will be requesting more regularly with confidence of gaining approval," added James Price, CEO of Everything Genetic, a company that provides consultation and sales support for the UK IVD market.

Details about how the insurers in question are determining coverage for the test in different types or stages of cancer were not disclosed.